期刊文献+

糖尿病肾病不同分期证候演变研究 被引量:29

TCM syndrome development research of diabetic nephropathy in different stage
原文传递
导出
摘要 目的:针对糖尿病肾病(DN)早期、临床期患者,开展糖尿病肾病不同分期证候演变研究。方法:收集早期DN及临床期DN的证候学资料,进行辨证及证素的提炼,对证候及证素进行统计学分析。结果:随着病情由早期演变到临床期,体现阴虚内热,热伤气阴病机的症状逐渐减少,阳虚的症状、证素呈现逐渐增多的趋势,临床期DN湿浊证素较早期DN逐渐增多。结论:DN病机从早期到临床期呈现气阴两虚发展向阴阳两虚的趋势,血瘀等邪实的证候贯穿早期和临床期,并有加重的趋势,其中湿浊证素较早期DN明显增加。 Targeted patients with early and clinical stage diabetic nephropathy(DN) to study TCM syndrome development of diabetic nephropathy in different stage.Methods: Collected TCM syndrome data of DN in early and clinical stages for syndrome differentiation and to refine the syndrome factors.And then the syndromes and syndrome factors were analyzed statistically.Results: As the disease evolved from the early stage to the clinical stage,the symptoms for internal heat induced byYin deficiency and heat hurt Qi and Yin were decreased,while the symptoms and syndrome factors for Yang deficiency were increased.The syndrome of dampness and turbid in early stage was more than the clinical stage of DN.Conclusion: From the early stage to the clinical stage,the pathogenesis of DN is from deficiency of both Qi and Yin to deficiency of both Yin and Yang,blood stasis is thoughout the whole stages and has worsening trend.The syndrome factor dampness and turbid in early stage was more opparent than the clinical stage of DN,which was always the key pathological factors.
出处 《中华中医药杂志》 CAS CSCD 北大核心 2012年第10期2687-2690,共4页 China Journal of Traditional Chinese Medicine and Pharmacy
基金 “十一五”国家科技支撑计划资助项目(No.2006BAI04A03-2)~~
关键词 证候特点 糖尿病肾病 证候演变规律 Characteristic of syndrome Diabetic nephropathy Syndrome development
  • 相关文献

参考文献2

二级参考文献22

  • 1王冰.黄帝内经素问[M].北京:人民卫生出版社,1963..
  • 2方药中.辨证论治七讲[M].北京:人民卫生出版社,1978,4..
  • 3中华医学会糖尿病学分会.中国2型糖尿病防治指南,2007.
  • 4Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med,1988, 318: 1315.
  • 5Wautier MP, Massin P, Guillausseau PJ, et al. N (carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes Metab,2003, 29:44.
  • 6Sourris KC, Forbes JM. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy -are these receptors valid therapeutic targets. Curr Drug Targets,2009, 10:42.
  • 7Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des, 2008, 14:953.
  • 8American Diabetes Association. Standards of medical care in diabetes -2008. Diabetes Care, 2005,31 (suppl 1 ) : S29.
  • 9Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem, 2006, 13:1971.
  • 10Tan KC, Shiu SW, Chow WS, et al. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia, 2006,49:2756.

共引文献298

同被引文献447

引证文献29

二级引证文献236

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部